NCT00401726

Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program

Patient Outcomes With Education, Drug Therapy, and Support (POETS): A Multicenter, Open-label, Randomized Study to Evaluate Depressed Subjects Treated With Venlafaxine Extended-release vs. Venlafaxine Extended-release Plus the Dialogues Time to Talk Program in a Primary Care Setting

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 537 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER). Dialogues Time to Talk Program is a patient management program, which aims to help patients achieve successful outcomes by reinforcing physician treatment efforts, providing feedback to treating physicians, and encouraging better physician-patient communications.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	Venlafaxine ER
BEHAVIORAL	Dialogues Time to Talk Program

Timeline

• Start date: 2006-06-01
• Completion: 2007-10-01
• First posted: 2006-11-20
• Last updated: 2012-04-23
• Results posted: 2010-06-29

Locations

44 sites across 1 country: United States